$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials
[Lowest Price Guaranteed: $2,995]

Published by Current Partnering: 01 Nov 2016 | 20161 | In Stock
Related Topics: Constipation , Financial , Gas , Pancreatitis , Technology

Introduction

Global Gastrointestinal Partnering 2010 to 2016 provides the full collection of Gastrointestinal disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.


Trends in Gastrointestinal partnering deals

Financial deal terms for headline, upfront and royalty by stage of development

Gastrointestinal partnering agreement structure

Gastrointestinal partnering contract documents

Top Gastrointestinal deals by value

Most active Gastrointestinal dealmakers


Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.


The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.


The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.


The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.


Chapter 1 provides an introduction to the report.


Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.


Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.


Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in Gastrointestinal partnering and dealmaking since 2010.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gastrointestinal technologies and products.


Report scope

Global Gastrointestinal Partnering 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to Gastrointestinal trends and structure of deals entered into by leading companies worldwide.


Global Gastrointestinal Partnering 2010 to 2016 includes:


Trends in Gastrointestinal dealmaking in the biopharma industry since 2010

Analysis of Gastrointestinal deal structure

Access to headline, upfront, milestone and royalty data

Access to hundreds of Gastrointestinal deal contract documents

Comprehensive access to over 3500 Gastrointestinal deal records

The leading Gastrointestinal deals by value since 2010

Most active Gastrointestinal dealmakers since 2010


The report includes deals for the following indications: Appendicitis, Celiac disease, Esophageal reflux, Esophagitis, Gastritis, Gastroenteritis, Hemorrhoids (haemorrhoids), Hernia, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Irritable bowel syndrome, Malabsorption, Malnutrition, Pancreatitis, Peptic ulce, Gastric ulcer, Duodenal ulcer, Abdominal pain, Ascites, Bowel movement, Constipation, Diarrhea, Jaundice, Vomitting, plus other gastrointestinal indications.


In Global Gastrointestinal Partnering 2010 to 2016, available deals and contracts are listed by:


Headline value

Upfront payment value

Royalty rate value

Stage of development at signing

Deal component type

Technology type

Specific therapy indication


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global Gastrointestinal Partnering 2010-2016 report provides comprehensive access to available deals and contract documents for over 400 gastrointestinal deals. Analyzing actual contract agreements allows assessment of the following:


What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How are the sales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Table of Contents
for Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in Gastrointestinal dealmaking

    2.1. Introduction

    2.2. Gastrointestinal partnering over the years

    2.3. Gastrointestinal partnering by deal type

    2.4. Gastrointestinal partnering by industry sector

    2.5. Gastrointestinal partnering by stage of development

    2.6. Gastrointestinal partnering by technology type

    2.7. Gastrointestinal partnering by therapeutic indication

    Chapter 3 –Financial deal terms for Gastrointestinal partnering

    3.1. Introduction

    3.2. Disclosed financials terms for Gastrointestinal partnering

    3.3. Gastrointestinal partnering headline values

    3.4. Gastrointestinal deal upfront payments

    3.5. Gastrointestinal deal milestone payments

    3.6. Gastrointestinal royalty rates

    Chapter 4 – Leading Gastrointestinal deals and dealmakers

    4.1. Introduction

    4.2. Most active in Gastrointestinal partnering

    4.3. List of most active dealmakers in Gastrointestinal

    4.4. Top Gastrointestinal deals by value

    Chapter 5 – Gastrointestinal contract document directory

    5.1. Introduction

    5.2. Gastrointestinal partnering deals where contract document available

    Chapter 6 – Gastrointestinal dealmaking by therapeutic target

    6.1. Introduction

    6.2. Deals by Gastrointestinal therapeutic target

    Appendices

    Appendix 1 – Directory of Gastrointestinal deals by company A-Z 2010 to 2016

    Appendix 2 – Directory of Gastrointestinal deals by deal type 2010 to 2016

    Appendix 3 – Directory of Gastrointestinal deals by stage of development 2010 to 2016

    Appendix 4 – Directory of Gastrointestinal deals by technology type 2010 to 2016

    Further reading on dealmaking

    Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from CurrentPartnering

    Table of figures

    Figure 1: Gastrointestinal partnering since 2010

    Figure 2: Gastrointestinal partnering by deal type since 2010

    Figure 3: Gastrointestinal partnering by industry sector since 2010

    Figure 4: Gastrointestinal partnering by stage of development since 2010

    Figure 5: Gastrointestinal partnering by technology type since 2010

    Figure 6: Gastrointestinal partnering by indication since 2010

    Figure 7: Gastrointestinal deals with a headline value

    Figure 8: Gastrointestinal deals with upfront payment values

    Figure 9: Gastrointestinal deals with milestone payment

    Figure 10: Gastrointestinal deals with royalty rates

    Figure 11: Active Gastrointestinal dealmaking activity– 2010 to 2016

    Figure 12: Top Gastrointestinal deals by value since 2010

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

20161 | CP2214

Number of Pages

700

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2016
Gastrointestinal Bleeding (Gastrointestinal Hemorrhage) Global Clinical Trials Review, H2, 2016Summa...
30 Nov 2016 by Global Data USD $2,500 More Info
Global Gastrointestinal Symptoms Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Nov 2016 by Current Partnering USD $1,495 More Info
Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials
Global Gastrointestinal Partnering 2010 to 2016 provides the full collection of Gastrointestinal dis...
01 Oct 2016 by Current Partnering USD $2,995 More Info
Global Gastrointestinal Symptoms Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape
Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies,...
13 Sep 2016 by GBI Research USD $4,995 More Info
Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape
Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies,...
13 Sep 2016 by GBI Research USD $4,995 More Info
North America Endoscopic Accessories Market - By Product (Carts, Cleaning Adapters, Lubrication Gel), By Application (Laparoscopy, Gastrointestinal Endoscopy), By Country (U.S. Canada Mexico) FORECASTS TO 2021
The North America endoscopic accessories market has been segmented based on product, application, an...
01 Aug 2016 by MicroMarketMonitor USD $2,650 More Info
North America Endoscopic Accessories Market - By Product (Carts, Cleaning Adapters, Lubrication Gel), By Application (Laparoscopy, Gastrointestinal Endoscopy), By Country (U.S. Canada Mexico) FORECASTS TO 2021
The North America endoscopic accessories market has been segmented based on product, application, an...
01 Aug 2016 by MarketsandMarkets USD $2,650 More Info
Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016
Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
31 May 2016 by Global Data USD $2,500 More Info
Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016
Gastrointestinal Stromal Tumor (GIST) Global Clinical Trials Review, H1, 2016SummaryGlobalData's cli...
31 May 2016 by Global Data USD $2,500 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Gastrointestinal Partnering 2010-2016: Deal trends, players and financials | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...